UNSPSC 51434819: Tefenperate

This classification denotes an antihypertensive agent with the molecular formula C29H37Cl2NO4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier W5P145L26T, chemically known as 2-(2,2,6,6-tetramethylpiperidino)ethyl 2-chlor-alpha-(2-chlorbenzyl)-alpha-hydroxyhydrocinnamat acetat but generally known as tefenperate, which bears US NIH Compound Identifier 163310. European Medicines Agency schedules Tefenperate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10866MIG.

UNSPSC 51434819 Tefenperate, a Commodity code, covers advanced life support medications and generic multi-source pharmaceuticals supplied to state and local public-sector health systems, emergency services, and pharmacy benefit programs. State and local governments buy under this code specific formulated medications in bulk — epinephrine, adenosine, labetalol, diltiazem, and other cardiac and emergency drugs — as well as generic and over-the-counter pharmaceutical products distributed through established wholesaler networks. Issuing bodies include city and county emergency medical services departments, state health and human services agencies, and multistate cooperative purchasing alliances representing hospital systems and government facilities across participating jurisdictions. The code attracts manufacturers and authorized pharmaceutical distributors rather than end-user procurement offices; vendors supply directly to wholesalers or fulfill line-item orders on fixed contracts with minimum shelf-life and expiration-date warranties typically running one to two years.

Activity spans Florida, Texas, and Minnesota with coordinated multistate reach through cooperative purchasing mechanisms. The City of Tampa's Purchasing Department issued IFB 26P00188 for Advanced Life Support Medications with a response deadline of April 8, 2026, seeking four medication line items (Labetalol, Epinephrine, Adenosine, Diltiazem) for Tampa Fire Rescue with an estimated contract value of $40,000 and a small local business enterprise bid discount; the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, posted RFP S1070000015802 for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline and a two-year contract term open to manufacturers willing to price through three authorized wholesalers and accept a 3 percent administrative fee. The Texas Health and Human Services Commission issued RFI HHS0017013 in late March 2026 to gather market intelligence on direct-to-manufacturer prescription delivery models outside traditional pharmacy benefit manager and wholesaler relationships, signaling state interest in alternative supply-chain structures. All recent solicitations require FDA compliance, current Good Manufacturing Practices certification, comprehensive insurance coverage, detailed product data (NDC codes, shelf life, expiration dates), and accessibility or safety documentation per federal and state standards.